# HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTT

> **NCT04618367** · NA · COMPLETED · sponsor: **Sun Yat-sen University** · enrollment: 30 (actual)

## Conditions studied

- Carcinoma, Hepatocellular
- Liver Neoplasms
- Sintilimab
- Portal Vein Tumor Thrombus

## Interventions

- **PROCEDURE:** Hepatic arterial infusion chemotherapy
- **DRUG:** Lenvatinib
- **DRUG:** Sintilimab

## Key facts

- **NCT ID:** NCT04618367
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-01
- **Primary completion:** 2021-12-30
- **Final completion:** 2022-12-30
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2024-03-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04618367

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04618367, "HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTT". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04618367. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*